ACE2 and COVID-19: It is unknown whether polymorphisms in ACE, or polymorphisms in ACE2 that may contribute to COVID-19 prognosis [see pre-prints (182, 183)], also determine the prognosis of patients in cardio-oncology treated with RAAS regulators, such as ACE inhibitors and ARBs.